From the early discovery through development of medicine, America’s biopharmaceutical companies are keeping patients at the center of the R&D process.
3 Reasons Patient Engagement is the Backbone of Scientific Discovery.
Each year, the National Health Council (NHC) convenes the Voluntary Health Leadership Conference (VHLC) – a forum that brings together patient advocacy organizations to share information about the latest in medical research and health care policy and provide a venue for sharing and discussing best practices.
Held this year in February, PhRMA CEO John Castellani attended the 28th annual event and discussed the critical importance of patient involvement in the drug discovery process. As John points out, patient engagement is critical to the research and development process for three central reasons:
First, industry scientists need to understand patient perspectives on the diseases they are working to treat and cure; second, critical to the development of new therapies is the involvement of patients to serve throughout the clinical trial process; and, finally – and once a medicine is approved – patient feedback is necessary for input and information about how a medicine is performing.
From the early stages of discovery to the time a medicines makes it way to the market, America’s biopharmaceutical companies are keeping patients at the center of the R&D process.
Learn more about the work of the National Health Council and take a few minutes to watch the videos from this year’s conference here.
Get updates on this subject and/or other relevant issues here. {{cta('4fe14269-44de-493b-a19c-946e0454614a')}}
